Abstract
The limitations of currently available drug therapies, particularly for the treatment of diseases localized in a specific organ or tissue, have encouraged scientists to consider alternative method of drug administration to increase their specificity. This is particularly relevant in the treatment of solid tumors and localized infections, where a high rate of recurrence remains a major clinical problem, associated with inadequate drug supply to the diseased site. An alternative treatment in the local administration of the agent from a degradable polymeric delivery system implanted at the site of the disease. In this fusion, the drug depot can maintain a high local concentration at the site for extended time periods with minimal systemic distribution of the drug. The polymer carrier is degraded and animated from the body shortly after the drug has been released.
Original language | English |
---|---|
Pages (from-to) | 134-139 |
Number of pages | 6 |
Journal | Molecular Medicine Today |
Volume | 1 |
Issue number | 3 |
DOIs | |
State | Published - Jun 1995 |
Externally published | Yes |
Bibliographical note
Funding Information:Acknowledgements. The work "described here involves collaboration with R. Langer, H. Brem, M.C. Davies, A. Shikni, M. Maniar, G. Golomb, M. Mayberga nd K. Byrd. A. Domb is supported by grants from NIH (UOl CA52857), Israel-US Science Foundation (910020), Israel Cancer Research Foundation (ICRF) and Israel Ministry of Health. A. Domb is affiliated with the David Bloom Center for Pharmacy.
Funding
Acknowledgements. The work "described here involves collaboration with R. Langer, H. Brem, M.C. Davies, A. Shikni, M. Maniar, G. Golomb, M. Mayberga nd K. Byrd. A. Domb is supported by grants from NIH (UOl CA52857), Israel-US Science Foundation (910020), Israel Cancer Research Foundation (ICRF) and Israel Ministry of Health. A. Domb is affiliated with the David Bloom Center for Pharmacy.
Funders | Funder number |
---|---|
Israel Cancer Research Foundation | |
Israel Ministry of Health | |
Israel-US Science Foundation | 910020 |
National Institutes of Health | |
National Cancer Institute | U01CA052857 |